Heart failure (HF) is a frequent and severe condition. It is estimated that one in four patients will die within a year following hospitalization for acute decompensation, with significant variations across age strata. A recent study reported that the 1-year mortality following hospitalization for HF was 9%, 14%, and 18% for patients under 55, between 55–64, and 65–74 years, respectively.1 Higher values

Among patients with cardiogenic shock, immediate initiation of extracorporeal membrane oxygenation (ECMO) did not demonstrate any benefit at 30 days. The present study evaluated 1-year clinical outcomes of the Extracorporeal Membrane Oxygenation in the therapy of Cardiogenic Shock (ECMO-CS) trial.

AimsHeart failure (HF) with preserved ejection fraction (HFpEF) reflects half of all clinical HF yet has few therapies. Obesity and diabetes are now common comorbidities which have focused attention towards underlying myocardial metabolic defects. The profile of a major metabolic pathway, glycolytic intermediates and their regulating enzymes and ancillary pathways, remains unknown.Methods and resultsEndomyocardial

AimsUnderstanding the pattern of disease progression in chronic heart failure (HF) may inform patient care and healthcare system design. We used a four‐state Markov model to describe the disease trajectory of patients with HF.Methods and resultsConsecutive patients (n = 4918) were enrolled (median age 75 [67–81] years, 61.3% men, 44% with HF and reduced ejection fraction). We generated a model by observing

The advent of immunological therapies has revolutionized the treatment of solid and haematological cancers over the last decade. Licensed therapies which activate the immune system to target cancer cells can be broadly divided into two classes. The first class are antibodies that inhibit immune checkpoint signalling, known as immune checkpoint inhibitors (ICIs). The second class are cell-based immune

Large clinical trials of intravenous iron for patients with heart failure have studied hospitalized patients immediately prior to discharge (AFFIRM-HF) and outpatients (HEART-FID)1-3; efficacy might differ by enrolment setting. IRONMAN (NCT02642562) was a prospective, randomized, open-label, blinded-endpoint trial comparing intravenous ferric derisomaltose (FDI) with usual care in patients with left